Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)

ANNALS OF ONCOLOGY

ELSEVIER

1. Bristol Myers Squibb Company (Princeton, NJ)
2. ONO Pharmaceutical Company Ltd. (Osaka, Japan)